Yangtze River Pharmaceutical Group

Taizhou, China

Yangtze River Pharmaceutical Group

Taizhou, China
SEARCH FILTERS
Time filter
Source Type

Zhang Z.,China Pharmaceutical University | Qi X.,China Pharmaceutical University | Li X.,China Pharmaceutical University | Xing J.,China Pharmaceutical University | And 3 more authors.
International Journal of Pharmaceutics | Year: 2014

Multilayer-coating technology is the traditional method to achieve pulsatile drug release with the drawbacks of time consuming, more materials demanding and lack of efficiency. The purpose of this study was to design a novel pulsatile drug delivery system based on the physiochemical interaction between acrylic copolymer and organic acid with relatively simpler formulation and manufacturing process. The Enalapril Maleate (EM) pulsatile release pellets were prepared using extruding granulation, spheronization and fluid-bed coating technology. The ion-exchange experiment, hydration study and determination of glass transition temperature were conducted to explore the related drug release mechanism. Bioavailability experiment was carried out by administering the pulsatile release pellets to rats compared with marketed rapid release tablets Yisu®. An obvious 4 h lag time period and rapid drug release was observed from in vitro dissolution profiles. The release mechanism was a combination of both disassociated and undisassociated forms of succinic acid physiochemically interacting with Eudragit® RS. The AUC0-τ of the EM pulsatile pellets and the market tablets was 702.384 ± 96.891 h ng/mL and 810.817 ± 67.712 h ng/mL, while the relative bioavailability was 86.62%. These studies demonstrate this novel pulsatile release concept may be a promising strategy for oral pulsatile delivery system. © 2013 Elsevier B.V.


Qi X.,China Pharmaceutical University | Chen H.,China Pharmaceutical University | Rui Y.,China Pharmaceutical University | Yang F.,China Pharmaceutical University | And 3 more authors.
International Journal of Pharmaceutics | Year: 2015

Abstract To prolong the residence time of dosage forms within gastrointestinal trace until all drug released at desired rate was one of the real challenges for oral controlled-release drug delivery system. Herein, we developed a fine floating tablet via compression coating of hydrophilic polymer (hydroxypropyl cellulose) combined with effervescent agent (sodium bicarbonate) to achieve simultaneous control of release rate and location of ofloxacin. Sodium alginate was also added in the coating layer to regulate the drug release rate. The effects of the weight ratio of drug and the viscosity of HPC on the release profile were investigated. The optimized formulations were found to immediately float within 30 s and remain lastingly buoyant over a period of 12 h in simulated gastric fluid (SGF, pH 1.2) without pepsin, indicating a satisfactory floating and zero-order drug release profile. In addition, the oral bioavailability experiment in New Zealand rabbits showed that, the relative bioavailability of the ofloxacin after administrated of floating tablets was 172.19%, compared to marketed common release tablets TaiLiBiTuo®. These results demonstrated that those controlled-released floating tables would be a promising gastro-retentive delivery system for drugs acting in stomach. © 2015 Elsevier B.V.


Gu L.,China Pharmaceutical University | Wu Z.H.,China Pharmaceutical University | Qi X.,China Pharmaceutical University | He H.,China Pharmaceutical University | And 5 more authors.
Pharmaceutical Development and Technology | Year: 2013

The potential of polyamidoamine (PAMAM) dendrimers as solubility enhancers and oral drug delivery system was well known. Herein, we investigated the possibility of PAMAM dendrimers for promoting the solubility and oral bioavailability of puerarin. In the present study, the effect of PAMAM dendrimers with different generations (G1.5, G2, G2.5, and G3) on the solubility of puerarin was evaluated at different concentrations and pH conditions. Further more, the puerarin-G2 dendrimer complex was conducted for the in vitro hemolytic toxicity studies and pharmacokinetics studies in rats. The solubility of puerarin was significantly higher in the presence of the full generation dendrimers (e.g. G2 and G3). No significant hemolysis was observed on erythrocytes (G2, 0-2.5 mg/mL) in the hemolytic toxicity studies. The pharmacokinetics parameters Tmax, Cmax, and AUC 0-8h of puerarin suspension solution and puerarin-G2 dendrimer complex solution were 0.76 h, 1.50 μg/mL, 7.33 μg•h/mL and 0.33 h, 6.49 μg/mL, 14.02 μg•h/mL, respectively. These studies demonstrate that PAMAM dendrimers may be a promising strategy for peroral delivery of puerarin. © 2013 Informa Healthcare USA, Inc.


News Article | November 30, 2016
Site: www.newsmaker.com.au

This report studies sales (consumption) of United States Glimepiride market, focuses on the top players, with sales, price, revenue and market share for each player, covering Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into Type I Type II Type III Split by applications, this report focuses on sales, market share and growth rate of Glimepiride in each application, can be divided into View Full Report With Complete TOC, List Of Figure and Table: http://globalqyresearch.com/united-states-glimepiride-market-report-2016 United States Glimepiride Market Report 2016 1 Glimepiride Overview 1.1 Product Overview and Scope of Glimepiride 1.2 Classification of Glimepiride 1.2.1 Type I 1.2.2 Type II 1.2.3 Type III 1.3 Application of Glimepiride 1.3.11 Blood sugar for people with type 2 diabetes 1.3.2 Application 2 1.3.3 Application 3 1.4 United States Market Size Sales (Value) and Revenue (Volume) of Glimepiride (2011-2021) 1.4.1 United States Glimepiride Sales and Growth Rate (2011-2021) 1.4.2 United States Glimepiride Revenue and Growth Rate (2011-2021) 5 United States Glimepiride Manufacturers Profiles/Analysis 5.1 Sanofi-Aventis 5.1.1 Company Basic Information, Manufacturing Base and Competitors 5.1.2 Glimepiride Product Type, Application and Specification 5.1.2.1 Type I 5.1.2.2 Type II 5.1.3 Sanofi-Aventis Glimepiride Sales, Revenue, Price and Gross Margin (2011-2016) 5.1.4 Main Business/Business Overview 5.2 Wanbang Biopharmaceuticals 5.2.2 Glimepiride Product Type, Application and Specification 5.2.2.1 Type I 5.2.2.2 Type II 5.2.3 Wanbang Biopharmaceuticals Glimepiride Sales, Revenue, Price and Gross Margin (2011-2016) 5.2.4 Main Business/Business Overview 5.3 Cspc Pharmaceutical 5.3.2 Glimepiride Product Type, Application and Specification 5.3.2.1 Type I 5.3.2.2 Type II 5.3.3 Cspc Pharmaceutical Glimepiride Sales, Revenue, Price and Gross Margin (2011-2016) 5.3.4 Main Business/Business Overview 5.4 Tianan Pharmaceutical 5.4.2 Glimepiride Product Type, Application and Specification 5.4.2.1 Type I 5.4.2.2 Type II 5.4.3 Tianan Pharmaceutical Glimepiride Sales, Revenue, Price and Gross Margin (2011-2016) 5.4.4 Main Business/Business Overview 5.5 Yangtze River Pharmaceutical Group 5.5.2 Glimepiride Product Type, Application and Specification 5.5.2.1 Type I 5.5.2.2 Type II 5.5.3 Yangtze River Pharmaceutical Group Glimepiride Sales, Revenue, Price and Gross Margin (2011-2016) 5.5.4 Main Business/Business Overview 5.6 Takeda Pharms USA 5.6.2 Glimepiride Product Type, Application and Specification 5.6.2.1 Type I 5.6.2.2 Type II 5.6.3 Takeda Pharms USA Glimepiride Sales, Revenue, Price and Gross Margin (2011-2016) 5.6.4 Main Business/Business Overview 5.7 Teva 5.7.2 Glimepiride Product Type, Application and Specification 5.7.2.1 Type I 5.7.2.2 Type II 5.7.3 Teva Glimepiride Sales, Revenue, Price and Gross Margin (2011-2016) 5.7.4 Main Business/Business Overview 5.8 Dr Reddys Labs Ltd 5.8.2 Glimepiride Product Type, Application and Specification 5.8.2.1 Type I 5.8.2.2 Type II 5.8.3 Dr Reddys Labs Ltd Glimepiride Sales, Revenue, Price and Gross Margin (2011-2016) 5.8.4 Main Business/Business Overview Global QYResearch is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.


Market Research Report Provides Manufacturers Profiles/Analysis: Novartis, Pfizer, Inc., Roche, Sanofi, Merck & Co., Inc., GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca plc., Eli Lilly and Company, Abbvie, AMGen, Teva Pharmaceutical Industries Ltd., Bayer AG, Bristol-Myers Squibb, Astellas Pharma, Daiichi Sankyo, Abbott Laboratories, Yangtze River Pharmaceutical Group, BAX & more -with detail like Company Basic Information, Manufacturing Base and Competitors. The report provides a basic overview of Lipid Regulating Drugs industry including definitions, applications and industry chain structure. United States market analysis and Chinese domestic market analysis are provided with a focus on history, developments, trends and competitive landscape of the market. A comparison between the international and Chinese situation is also offered. United States Lipid Regulating Drugs Industry Research Report 2016 also focuses on development policies and plans for the industry as well as a consideration of a cost structure analysis. Capacity production, market share analysis, import and export consumption and price cost production value gross margins are discussed. A key feature of this report is it focus on major industry players, providing an overview, product specification, product capacity, production price and contact information for United States Top15 companies. This enables end users to gain a comprehensive insight into the structure of the international and Chinese Lipid Regulating Drugs industry. Development proposals and the feasibility of new investments are also analyzed. Companies and individuals interested in the structure and value of the Lipid Regulating Drugs industry should consult this report for guidance and direction. The report begins with a brief overview of the United States Lipid Regulating Drugs market and then moves on to evaluate the key trends of the market. The key trends shaping the dynamics of the United States Lipid Regulating Drugs market have been scrutinized along with the related current events, which is impacting the market. Drivers, restraints, opportunities, and threats of the United States Lipid Regulating Drugs market have been analyzed in the report. Moreover, the key segments and the sub-segments that constitutes the market is also explained in the report.


This report studies sales (consumption) of Global Vitamin Drugs Market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Vitamin Drugs in these regions, from 2011 to 2021 (forecast), like North America China Europe Japan Southeast Asia India Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into Fat-soluble Vitamins Water-soluble Vitamins Type III Split by applications, this report focuses on sales, market share and growth rate of Vitamin Drugs in each application, can be divided into First Level Hospital Two Level Hospital Three Level Hospital Others 1 Vitamin Drugs Overview 1.1 Product Overview and Scope of Vitamin Drugs 1.2 Classification of Vitamin Drugs 1.2.1 Fat-soluble Vitamins 1.2.2 Water-soluble Vitamins 1.2.3 Type III 1.3 Applications of Vitamin Drugs 1.3.1 First Level Hospital 1.3.2 Two Level Hospital 1.3.3 Three Level Hospital 1.3.4 Others 1.4 Vitamin Drugs Market by Regions 1.4.1 North America Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.4.5 Southeast Asia Status and Prospect (2011-2021) 1.4.6 India Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Vitamin Drugs (2011-2021) 1.5.1 Global Vitamin Drugs Sales, Revenue and Price (2011-2021) 1.5.2 Global Vitamin Drugs Sales and Growth Rate (2011-2021) 1.5.3 Global Vitamin Drugs Revenue and Growth Rate (2011-2021) 9 Global Vitamin Drugs Manufacturers Analysis 9.1 Novartis 9.1.1 Company Basic Information, Manufacturing Base and Competitors 9.1.2 Vitamin Drugs Product Type and Technology 9.1.2.1 Fat-soluble Vitamins 9.1.2.2 Water-soluble Vitamins 9.1.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2016) 9.2 Pfizer, Inc. 9.2.1 Company Basic Information, Manufacturing Base and Competitors 9.2.2 Vitamin Drugs Product Type and Technology 9.2.2.1 Fat-soluble Vitamins 9.2.2.2 Water-soluble Vitamins 9.2.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2016) 9.3 Roche 9.3.1 Company Basic Information, Manufacturing Base and Competitors 9.3.2 Vitamin Drugs Product Type and Technology 9.3.2.1 Fat-soluble Vitamins 9.3.2.2 Water-soluble Vitamins 9.3.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2016) 9.4 Sanofi 9.4.1 Company Basic Information, Manufacturing Base and Competitors 9.4.2 Vitamin Drugs Product Type and Technology 9.4.2.1 Fat-soluble Vitamins 9.4.2.2 Water-soluble Vitamins 9.4.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2016) 9.5 Merck & Co., Inc. 9.5.1 Company Basic Information, Manufacturing Base and Competitors 9.5.2 Vitamin Drugs Product Type and Technology 9.5.2.1 Fat-soluble Vitamins 9.5.2.2 Water-soluble Vitamins 9.5.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2016) 9.6 GlaxoSmithKline plc 9.6.1 Company Basic Information, Manufacturing Base and Competitors 9.6.2 Vitamin Drugs Product Type and Technology 9.6.2.1 Fat-soluble Vitamins 9.6.2.2 Water-soluble Vitamins 9.6.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2016) 9.7 Johnson & Johnson 9.7.1 Company Basic Information, Manufacturing Base and Competitors 9.7.2 Vitamin Drugs Product Type and Technology 9.7.2.1 Type I 9.7.2.2 Type II 9.7.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2017) 9.8 AstraZeneca plc. 9.8.1 Company Basic Information, Manufacturing Base and Competitors 9.8.2 Vitamin Drugs Product Type and Technology 9.8.2.1 Type I 9.8.2.2 Type II 9.8.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2018) 9.9 Eli Lilly and Company 9.9.1 Company Basic Information, Manufacturing Base and Competitors 9.9.2 Vitamin Drugs Product Type and Technology 9.9.2.1 Type I 9.9.2.2 Type II 9.9.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2019) 9.10 Abbvie 9.10.1 Company Basic Information, Manufacturing Base and Competitors 9.10.2 Vitamin Drugs Product Type and Technology 9.10.2.1 Type I 9.10.2.2 Type II 9.10.3 Vitamin Drugs Sales, Revenue, Price of Company One (2015 and 2021) 9.11 AMGen 9.12 Teva Pharmaceutical Industries Ltd. 9.13 Bayer AG 9.14 Bristol-Myers Squibb 9.15 Astellas Pharma 9.16 Daiichi Sankyo 9.17 Abbott Laboratories 9.18 Yangtze River Pharmaceutical Group 9.19 Taish? Seiyaku Kabushiki-gaisha Global QYResearch (http://globalqyresearch.com/ ) is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.


This report studies sales (consumption) of Global Sex Hormones and Birth Control Pills Market 2016, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Sex Hormones and Birth Control Pills in these regions, from 2011 to 2021 (forecast), like North America China Europe Japan Southeast Asia India Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into Male Hormone Drugs Female Hormone Drugs Progesterone Drugs Split by applications, this report focuses on sales, market share and growth rate of Sex Hormones and Birth Control Pills in each application, can be divided into First Level Hospital Two Level Hospital Three Level Hospital Others 1 Sex Hormones and Birth Control Pills Overview 1.1 Product Overview and Scope of Sex Hormones and Birth Control Pills 1.2 Classification of Sex Hormones and Birth Control Pills 1.2.1 Male Hormone Drugs 1.2.2 Female Hormone Drugs 1.2.3 Progesterone Drugs 1.3 Applications of Sex Hormones and Birth Control Pills 1.3.1 First Level Hospital 1.3.2 Two Level Hospital 1.3.3 Three Level Hospital 1.3.4 Others 1.4 Sex Hormones and Birth Control Pills Market by Regions 1.4.1 North America Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.4.5 Southeast Asia Status and Prospect (2011-2021) 1.4.6 India Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Sex Hormones and Birth Control Pills (2011-2021) 1.5.1 Global Sex Hormones and Birth Control Pills Sales, Revenue and Price (2011-2021) 1.5.2 Global Sex Hormones and Birth Control Pills Sales and Growth Rate (2011-2021) 1.5.3 Global Sex Hormones and Birth Control Pills Revenue and Growth Rate (2011-2021) 9 Global Sex Hormones and Birth Control Pills Manufacturers Analysis 9.1 Novartis 9.1.1 Company Basic Information, Manufacturing Base and Competitors 9.1.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.1.2.1 Male Hormone Drugs 9.1.2.2 Female Hormone Drugs 9.1.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2016) 9.2 Pfizer, Inc. 9.2.1 Company Basic Information, Manufacturing Base and Competitors 9.2.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.2.2.1 Male Hormone Drugs 9.2.2.2 Female Hormone Drugs 9.2.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2016) 9.3 Roche 9.3.1 Company Basic Information, Manufacturing Base and Competitors 9.3.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.3.2.1 Male Hormone Drugs 9.3.2.2 Female Hormone Drugs 9.3.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2016) 9.4 Sanofi 9.4.1 Company Basic Information, Manufacturing Base and Competitors 9.4.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.4.2.1 Male Hormone Drugs 9.4.2.2 Female Hormone Drugs 9.4.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2016) 9.5 Merck & Co., Inc. 9.5.1 Company Basic Information, Manufacturing Base and Competitors 9.5.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.5.2.1 Male Hormone Drugs 9.5.2.2 Female Hormone Drugs 9.5.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2016) 9.6 GlaxoSmithKline plc 9.6.1 Company Basic Information, Manufacturing Base and Competitors 9.6.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.6.2.1 Male Hormone Drugs 9.6.2.2 Female Hormone Drugs 9.6.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2016) 9.7 Johnson & Johnson 9.7.1 Company Basic Information, Manufacturing Base and Competitors 9.7.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.7.2.1 Type I 9.7.2.2 Type II 9.7.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2017) 9.8 AstraZeneca plc. 9.8.1 Company Basic Information, Manufacturing Base and Competitors 9.8.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.8.2.1 Type I 9.8.2.2 Type II 9.8.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2018) 9.9 Eli Lilly and Company 9.9.1 Company Basic Information, Manufacturing Base and Competitors 9.9.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.9.2.1 Type I 9.9.2.2 Type II 9.9.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2019) 9.10 Abbvie 9.10.1 Company Basic Information, Manufacturing Base and Competitors 9.10.2 Sex Hormones and Birth Control Pills Product Type and Technology 9.10.2.1 Type I 9.10.2.2 Type II 9.10.3 Sex Hormones and Birth Control Pills Sales, Revenue, Price of Company One (2015 and 2021) 9.11 AMGen 9.12 Teva Pharmaceutical Industries Ltd. 9.13 Bayer AG 9.14 Bristol-Myers Squibb 9.15 Astellas Pharma 9.16 Daiichi Sankyo 9.17 Abbott Laboratories 9.18 Yangtze River Pharmaceutical Group 9.19 Taish? Seiyaku Kabushiki-gaisha Global QYResearch (http://globalqyresearch.com/ ) is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.


Peng J.,China Pharmaceutical University | Qi X.,China Pharmaceutical University | Chen Y.,China Pharmaceutical University | Ma N.,China Pharmaceutical University | And 6 more authors.
Journal of Drug Targeting | Year: 2014

Purpose: An octreotide-conjugated polyamidoamine (PAMAM) dendrimer was synthesized and employed as nanocarriers of methotrexate (MTX), for targeting to the somatostatin receptors over-expressed tumor cells. Methods: PAMAM-PEG-octreotide (PPO) and PAMAM-PEG (PPG) were synthesized and characterized. The cellular uptake of fluorescein isothiocyanate (FITC)-labeled PPO (PPO-FITC) and PPG (PPG-FITC) were investigated. The cytotoxicity of MTX and MTX nanoparticles were conducted in the MCF-7 cells. Besides, the pharmacokinetics studies on MTX nanoparticles were carried out in rats. Results: The structure of PPO was verified by NMR detection and the diameter was 11.05 ± 1.80 nm, with the amount of MTX encapsulated by PPO was 30 (molecule/molecule). MTX nanoparticles possessed significantly higher cytotoxicity against MCF-7 cells compared with free MTX, especially the PPO/MTX nanoparticles. Correspondingly, the PPO-FITC carrier had higher cellular uptake efficiency compared to PPG-FITC. In addition, pharmacokinetics studies showed that PPO/MTX nanoparticles increased mean residence time and bioavailability of MTX distinctly. Discussion and conclusion: With further cellular uptake test of FITC-labeled carriers, the enhanced cytotoxicity of PPO/MTX nanoparticles was reasonable to ascribe to the specific receptor-mediated endocytosis induced by octreotide. The present study suggests that this PAMAM-PEG-octreotide nanocarrier opens a new path for treating cancer with higher efficacy. © 2014 Informa UK Ltd. All rights reserved: reproduction in whole or part not permitted.


Zhang T.,Shenyang Pharmaceutical University | Sun Y.,Shenyang Pharmaceutical University | Zhang P.,Shenyang Pharmaceutical University | Gao J.,Yangtze River Pharmaceutical Group | And 2 more authors.
Biomedical Chromatography | Year: 2013

A rapid, sensitive and selective ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for the determination of febuxostat in dog plasma. Using paclitaxel as an internal standard (IS), a simple liquid-liquid extraction method with ethyl acetate was adopted for plasma sample pretreatment. Separation was carried out on an Acquity UPLC BEH C18 column with a mobile phase consisting of acetonitrile and water (containing 0.2% formic acid). The assay was linear in the concentration ranged from 5 to 5000 ng/mL with a lower limit of quantification of 5 ng/mL for febuxostat. The single run analysis was as short as 2.0 min. Finally, the developed method was successfully applied to the pharmacokinetic study of febuxostat tablets following oral administration at a single dose of 40 mg in beagle dogs. © 2012 John Wiley & Sons, Ltd.


Qi X.,China Pharmaceutical University | Qin J.,China Pharmaceutical University | Ma N.,China Pharmaceutical University | Chou X.,China Pharmaceutical University | And 2 more authors.
International Journal of Pharmaceutics | Year: 2014

The aims of this study were to choose a suitable adsorbent of self-microemulsion and to develop a fine solid self-microemulsifying dispersible tablets for promoting the dissolution and oral bioavailability of celastrol. Solubility test, self-emulsifying grading test, droplet size analysis and ternary phase diagrams test were performed to screen and optimize the composition of liquid celastrol self-microemulsifying drug delivery system (SMEDDS). Then microcrystalline cellulose KG 802 was added as a suitable adsorbent into the optimized liquid celastrol-SMEDDS formulation to prepare the dispersible tablets by wet granulation compression method. The optimized formulation of celastrol-SMEDDS dispersible tablets was finally determinated by the feasibility of the preparing process and redispersibility. The in vitro study showed that the dispersible tablets could disperse in the dispersion medium within 3 min with the average particle size of 25.32 ± 3.26 nm. In vivo pharmacokinetic experiments of rats, the relative bioavailability of celastrol SMEDDS and SMEDDS dispersible tablets compared to the 0.4% CMC-Na suspension was 569 ± 7.07% and 558 ± 6.77%, respectively, while there were no significant difference between the SMEDDS and SMEDDS dispersible tablets. The results suggest the potential use of SMEDDS dispersible tablets for the oral delivery of poorly water-soluble terpenes drugs, such as celastrol. © 2014 Published by Elsevier B.V. All rights reserved.

Loading Yangtze River Pharmaceutical Group collaborators
Loading Yangtze River Pharmaceutical Group collaborators